Influencing Risk Factors of Voriconazole-induced Liver Injury in Uygur Pediatric Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal BMC Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2024 May 3

PMID 38702595

Authors

Ting Zhao

Hui-Lan Zhang

Hao Shen

Jie Feng

Ting-Ting Wang

Hong-Jian Li

Lu-Hai Yu

Affiliations

Soon will be listed here.

Abstract

Purpose: We aimed to investigated the influencing risk factors of voriconazole-induced liver injury in Uygur pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Methods: This was a prospective cohort design study. High-performance liquid chromatography-mass spectrometry was employed to monitor voriconazole concentration. First-generation sequencing was performed to detect gene polymorphisms. Indicators of liver function were detected at least once before and after voriconazole therapy.

Results: Forty-one patients were included in this study, among which, 15 patients (36.6%) had voriconazole-induced liver injury. The proportion of voriconazole trough concentration > 5.5 μg·mL patients within the DILI group (40.0%) was significantly higher compared to the control group (15.4%) (p < 0.05). After administration of voriconazole, the values of ALT (103.3 ± 80.3 U/L) and AST (79.9 ± 60.6 U/L) in the DILI group were higher than that in the control group (24.3 ± 24.8 and 30.4 ± 8.6 U/L) (p < 0.05). There was no significant difference between the two groups in genotype and allele frequencies of CYP2C19*2, CYP2C19*3, CYP2C19*17, and UGT1A4 (rs2011425) (p > 0.05).

Conclusion: There was a significant correlation between voriconazole-induced liver injury and voriconazole trough concentration in high-risk Uygur pediatric patients with allogeneic HSCT.

References

Kato K, Nagao M, Yamamoto M, Matsumura Y, Takakura S, Fukuda K . Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients. J Infect Chemother. 2015; 22(1):27-31. DOI: 10.1016/j.jiac.2015.09.008. View

Amsden J, Gubbins P . Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 2017; 13(11):1135-1146. DOI: 10.1080/17425255.2017.1391213. View

Alcazer V, Conrad A, Valour F, Bachy E, Salles G, Huynh A . Early-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure. Am J Hematol. 2019; 94(4):E109-E111. DOI: 10.1002/ajh.25406. View

Li X, Yu C, Wang T, Chen K, Zhai S, Tang H . Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2016; 72(10):1185-1193. DOI: 10.1007/s00228-016-2089-y. View

Song Y, Jia M, Yang G, Feng X, Yin D, Kang J . Association of and polymorphisms with voriconazole-induced liver injury. Per Med. 2019; 17(1):15-22. DOI: 10.2217/pme-2019-0042. View

Kim S, Lee D, Kwon J, Lee H, Cho S, Park C . Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population. Infect Chemother. 2014; 45(4):406-14. PMC: 3902809. DOI: 10.3947/ic.2013.45.4.406. View

Hao J, Chen Y, Li S, Zhang P, Yu Y, Tang G . [Relationship between the polymorphisms of UGT1A6 genes and anti-tuberculosis drug induced hepatic-injury]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(3):201-4. DOI: 10.3760/cma.j.issn.1007-3418.2011.03.012. View

Matsumoto K, Abematsu K, Shigemi A, Kanazawa N, Watanabe E, Yokoyama Y . Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data. J Chemother. 2015; 28(3):198-202. DOI: 10.1179/1973947815Y.0000000057. View

Bourcier K, Hyland R, Kempshall S, Jones R, Maximilien J, Irvine N . Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010; 38(6):923-9. DOI: 10.1124/dmd.109.030676. View

10.

Taghvaye Masoumi H, Hadjibabaie M, Vaezi M, Ghavamzadeh A . Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients. J Res Pharm Pract. 2017; 6(2):77-82. PMC: 5463553. DOI: 10.4103/jrpp.JRPP_16_163. View

11.

Ghannoum M, Kuhn D . Voriconazole -- better chances for patients with invasive mycoses. Eur J Med Res. 2002; 7(5):242-56. View

12.

Barbarino J, Obeng A, Klein T, Altman R . PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenet Genomics. 2017; 27(5):201-209. PMC: 5405706. DOI: 10.1097/FPC.0000000000000276. View

13.

Caudle K, Dunnenberger H, Freimuth R, Peterson J, Burlison J, Whirl-Carrillo M . Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2016; 19(2):215-223. PMC: 5253119. DOI: 10.1038/gim.2016.87. View

14.

Daly A, Aithal G, Leathart J, Swainsbury R, Dang T, Day C . Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007; 132(1):272-81. DOI: 10.1053/j.gastro.2006.11.023. View

15.

Hirata A, Noto K, Ota R, Yokoyama S, Hosomi K, Takada M . Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin . Int J Clin Pharmacol Ther. 2019; 57(3):135-143. DOI: 10.5414/CP203345. View

16.

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

17.

Sun Y, Huang H, Chen J, Li J, Ma J, Li J . Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol. 2014; 36(2):757-67. DOI: 10.1007/s13277-014-2649-7. View

18.

Chan S, Chua A, Aminkeng F, Chee C, Jin S, Loh M . Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. PLoS One. 2017; 12(10):e0186200. PMC: 5642896. DOI: 10.1371/journal.pone.0186200. View

19.

Xu S, Liu L, Chen Y, Liu M, Lu T, Wang H . Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. Eur J Clin Pharmacol. 2018; 74(5):583-591. DOI: 10.1007/s00228-018-2414-8. View

20.

Thomsen K, Macnaughtan J, Tritto G, Mookerjee R, Jalan R . Clinical and Pathophysiological Characteristics of Cirrhotic Patients with Grade 1 and Minimal Hepatic Encephalopathy. PLoS One. 2016; 11(1):e0146076. PMC: 4706303. DOI: 10.1371/journal.pone.0146076. View